MetaCap

Ginkgo Bioworks Holdings Inc. Class A (DNA)

NYSE: DNAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

7.46-0.74 (-9.02%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

DNA stock chart

Technical analysis

Key statistics

All statistics
Market cap
$483.54M
EPS (TTM)
-$4.24
52-week range
5.37 – 18.22
Day range
7.39 – 8.28
Volume / Avg
2.50M / 2.53M
Beta
—

52-week range

$5.37$18.22

DNA stock today

Shares of Ginkgo Bioworks (DNA) finished lower on Nov 20 at $7.46, a drop of 9.02% or $0.74 per share, versus the S&P 500's 3.70% decline. Shares are 59.1% below their 52-week high of $18.22, set on Oct 6, 2026 and 38.9% above the 52-week low of $5.37, near the bottom of the past year's range. DNA is down 10.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 8.7%.

Ginkgo Bioworks has posted a net loss over the last twelve months (EPS of -$4.24), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Ginkgo Bioworks

Company profile

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Jason Kelly Ph.D.
Headquarters
Boston, MA
Employees
485
IPO year
2021
Website
ginkgo.bio

Financial highlights

Full financials

In fiscal 2025, Ginkgo Bioworks generated $170.2 million in revenue, down 25.1% from fiscal 2024, its first annual decline since 2024. Ginkgo Bioworks reported a net loss of $312.8 million, compared with a loss of $547.0 million a year earlier. Operating margin was -185.3%.

Ginkgo Bioworks annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$170.16M$227.04M$251.46M$477.71M$313.84M
Growth-25.06%-9.71%-47.36%+52.21%+309.40%
Net income$-312.76M$-547.03M$-892.87M$-2.10B$-1.83B
EPS (diluted)$-5.64$-10.54$-18.37$-50.20$-1.39

Analyst forecast

Forecast

Consensus (3 analysts)

underperform

Avg. price target

$8.00+7.24%

  • Strong buy 0
  • Buy 0
  • Hold 1
  • Sell 1
  • Strong sell 1

Target range

Low $5.00High $11.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$-1.45 vs $-0.58
Surprise
-150.00%

DNA news

All DNA news

Ginkgo Bioworks peers

Health Care sector
DNA peer companies
CompanyPrice% ChgMarket capCompare
SANASana Biotechnology Inc.1.59-8.62%$476.42Mvs DNA
VALNValneva SE ADR5.16-3.82%$490.86Mvs DNA
RGNXREGENXBIO Inc.7.16-0.28%$473.44Mvs DNA
FENCFennec Pharmaceuticals Inc.13.09-2.68%$462.14Mvs DNA
ETRAElectra Therapeutics Inc.8.11-9.28%$509.85Mvs DNA
IRLAIRulya Therapeutics Inc.39.88-0.15%$432.36Mvs DNA
PROKProKidney Corp. Class A1.04-1.89%$415.21Mvs DNA
TECXTectonic Therapeutic Inc.20.73-1.47%$405.26Mvs DNA

Indexes, lists and sector

Ginkgo Bioworks stock FAQ

What is Ginkgo Bioworks's stock price today?

DNA last traded at $7.46 as of Nov 20, 4:00 PM EST, down 9.02% on the day. Prices are delayed at least 15 minutes.

Does Ginkgo Bioworks pay a dividend?

No. Ginkgo Bioworks does not currently pay a regular cash dividend.

Who is Ginkgo Bioworks's CEO?

Dr. Jason Kelly Ph.D. is the chief executive officer of Ginkgo Bioworks Holdings Inc. Class A, which has about 485 employees.

Has DNA ever split its stock?

Yes. The most recent DNA stock split was a 1-for-40 split on Aug 20, 2024.

What is the DNA 52-week high?

The 52-week high for DNA is $18.22 and the 52-week low is $5.37. The stock is currently 59.1% below its high.

Compare DNA